NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis (Q2907213): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Changed an Item) |
||||||||||||||
| Property / beneficiary name (string) | |||||||||||||||
| Property / beneficiary name (string): BSIM THERAPEUTICS, S.A. / rank | |||||||||||||||
| Property / beneficiary | |||||||||||||||
| Property / beneficiary: Q2988326 (Deleted Item) / rank | |||||||||||||||
| Property / budget | |||||||||||||||
| |||||||||||||||
| Property / budget: 1,136,307.6 Euro / rank | |||||||||||||||
| Property / EU contribution | |||||||||||||||
| |||||||||||||||
| Property / EU contribution: 891,220.51 Euro / rank | |||||||||||||||
| Property / co-financing rate | |||||||||||||||
| |||||||||||||||
| Property / co-financing rate: 78.43 percent / rank | |||||||||||||||
| Property / date of last update | |||||||||||||||
| |||||||||||||||
| Property / date of last update: 23 May 2023 / rank | |||||||||||||||
| Property / beneficiary | |||||||||||||||
| Property / beneficiary: BSIM THERAPEUTICS, S.A. / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / beneficiary name (string) | |||||||||||||||
BSIM THERAPEUTICS, S.A. | |||||||||||||||
| Property / beneficiary name (string): BSIM THERAPEUTICS, S.A. / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / budget | |||||||||||||||
934,289.9 Euro
| |||||||||||||||
| Property / budget: 934,289.9 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / EU contribution | |||||||||||||||
722,832.3 Euro
| |||||||||||||||
| Property / EU contribution: 722,832.3 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / co-financing rate | |||||||||||||||
77.37 percent
| |||||||||||||||
| Property / co-financing rate: 77.37 percent / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / date of last update | |||||||||||||||
14 November 2023
| |||||||||||||||
| Property / date of last update: 14 November 2023 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Revision as of 17:27, 14 November 2023
Project Q2907213 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis |
Project Q2907213 in Portugal |
Statements
722,832.3 Euro
0 references
934,289.9 Euro
0 references
77.37 percent
0 references
16 August 2016
0 references
15 February 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
14 November 2023
0 references
Identifiers
POCI-01-0247-FEDER-003431
0 references